ontunisertib

Small molecule

Phase 2topline reported

Evidence outlook

Fibrostenosing Crohn's Disease: topline reported 2026-10-01

The sponsor reported topline results on 2026-10-01 (STENOVA open-label extension topline of ontunisertib in fibrostenosing Crohn's disease). The announcement is listed under Regulatory events.

Featured evidence outside this drug's tracked markets:NCT05937386 · Healthy Volunteers · Phase 1 · completed · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Fibrostenosing Crohn's Disease
Phase 1 (4)
Fibrostenosing Crohn's Disease
NCT07672574 · Agomab Spain S.L.U.
2026-09-09 – 2027-01-31 · Fibrostenotic Crohn's Disease
What this study did
NCT07118878 · Agomab Spain S.L.U.
2025-08-06 – 2025-09-15 · Fibrostenotic Crohn's Disease
What this study did
Other / comorbidity
NCT06397508 · Agomab Spain S.L.
2024-04-02 – 2024-05-13 · Healthy Volunteers
What this study did
NCT05937386 · Agomab Spain S.L.
2023-08-09 – 2023-09-06 · Healthy Volunteers
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ontunisertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 1Fibrostenosing Crohn's DiseaseRecruiting
Est. primary completion 2027-01-31 · NCT07672574 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 2Fibrostenosing Crohn's DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT07683325 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 October 2026Topline resultSTENOVA open-label extension topline of ontunisertib in fibrostenosing Crohn's disease
Agomab Therapeutics NV · Source ↗